As the world's highest hematology event, the 65th Annual meeting of the American Society of Hematology (ASH) will be held in San Diego, USA, from December 9 to 12, 2023. This conference shares the latest research results, treatments, clinical trials and other information related to blood disorders. The publication of preclinical data on transdermal curcumin in the treatment of sickle cell disease has attracted wide attention.
Preclinical results showed a steady reduction in pain, an increase in red blood cell stability, and a reduction in inflammatory markers.
About human sickle cell disease
Sickle cell disease is the most common genetic disorder that primarily affects African Americans and Hispanics in the United States, with approximately 50% of affected individuals suffering from chronic pain.
Vascarta is a start-up pharmaceutical company dedicated to exploring effective transdermal drug delivery to address inflammation and blood disorders.
Vascarta transdermal curcumin gel has a solubility more than 100 times greater than conventional curcumin topics and enhances deep penetration of curcumin into the skin when applied topially (US Patent 11,484,493). For other topical curcumin preparations, the low concentration and lack of deep penetration results in curcumin being confined to the vaseless superficial layer of the skin, resulting in little or no systemic delivery to the circulatory system. The resulting waterless and highly stable Vascarta curcumin gel is not only able to penetrate into the skin longer than traditional gel, cream or ointment techniques, but, unlike curcumin oral solution, it can quickly and efficiently enter capillaries, even the smallest and tiniest blood vessels.
Curcumin is a bright yellow compound isolated from the turmeric plant (Zingiberaceae). Turmeric has traditionally been used in botanical pharmacy as a traditional medicine to treat skin and gastrointestinal inflammation, control weight and indigestion. Curcumin is recognized as a safe compound by the U.S. Food and Drug Administration (FDA). Numerous preclinical and clinical studies have evaluated the safety of the compound, with curcumin not detected in the serum of healthy subjects taking 8,000 mg per day and only low levels detected in two subjects taking 10,000 or 12,000 mg per day. No harmful effects were observed in any of the subjects and 12,000 mg per day is safe for healthy individuals.
Curcumin shows poor bioavailability due to its low solubility and low stability in water, and most of the products provided by the global curcumin market are nutritional supplements, and few drugs have been approved for listing.
Image source: Internet
Over the past decade, researchers have experimented with new pharmaceutical approaches to improve the bioavailability of curcumin using nanoparticles, liposomes, micelles, solid dispersions, emulsions, and microspheres. The development of transdermal, quantitable curcumin preparations that can quickly enter the subcutaneous microcirculation system into the systemic circulatory system can make efficient use of API, and solve the limitations of drug delivery methods such as high oral dose inefficiency and gastrointestinal stimulation and injection on vascular stimulation.
Lindmik Pharmaceutical(Suzhou)Co.,Ltd is a high-tech pharmaceutical enterprise focusing on the research and development, production and sales of innovative pharmaceutical preparations.Equipped with a number of its own innovative R&D platform of dosage forms, including the transdermal drug delivery system, and at the same time, actively introducing the world’s leading nano-based drug delivery, microspheres drug delivery and other cutting-edge pharmaceutical technologies by means of “license in”, the company is a new rapidly developing company pharmaceutical companies that catches people’s eyes.
12th Floor, Building 5, Tianyun Plaza, 111 Wusongjiang Avenue, Guoxiang Street, Wuzhong District, Suzhou City
0512-66020899
0512-66022699
215124